Delta Sleep-Inducing Peptide Doesn't Meaningfully Improve Sleep in Insomniacs

What the researchers found

Delta sleep-inducing peptide (DSIP) administered intravenously at 25 nmol/kg over four nights showed some improvements in sleep metrics in chronic insomniacs — including reduced awakenings, decreased waking time, and increased total sleep time — but these changes were not statistically significant compared to placebo. The only significant increases were in NREM sleep time and stage 2 sleep, but these differences already existed at baseline, undermining the finding. The authors concluded that DSIP's sleep-improving effects are of little clinical significance.

Why it matters

DSIP was once considered a promising natural sleep peptide, but this rigorous double-blind, placebo-controlled trial found it doesn't meaningfully improve sleep in chronic insomniacs. This is an important negative result that helps explain why DSIP never became a clinical sleep treatment despite decades of interest. It underscores the gap between a peptide's name and its actual therapeutic utility.

The numbers in context

25 nmol/kg dose · 4 nights treatment · Double-blind crossover · NREM sleep and stage 2 increased but not beyond baseline differences

How the study worked

This was a double-blind, placebo-controlled crossover trial in chronic insomnia patients. DSIP (25 nmol/kg) or placebo was administered intravenously over four nights. Sleep was measured using polysomnographic recordings, tracking sleep stages, awakenings, latency, and total sleep time.

Who was studied

Adult chronic insomnia patients (both male and female)

What this study cannot tell us

Sample size not specified in abstract but likely small. The short 4-night treatment period may not capture potential longer-term effects. Only one dose was tested. The IV route of administration limits practical applicability. The crossover design, while rigorous, may have been affected by carryover or period effects.

How to read the evidence

This is a moderate-strength study due to its rigorous double-blind, crossover, placebo-controlled design. However, the small sample size and short duration temper the strength of its negative conclusion.

When this study was published

Published in 1987. This is a historically important study that helped establish that DSIP lacks clinical utility for insomnia. The negative finding has been largely confirmed by subsequent research over the decades.

The bigger picture

DSIP was discovered in 1977 and generated enormous excitement as a potential natural sleep drug. This 1987 trial was one of several that ultimately showed it doesn't live up to its name in clinical settings. The story of DSIP illustrates a common pattern in peptide research: a molecule discovered through its effects in animal models fails to translate to meaningful therapeutic benefit in humans. Despite this, DSIP remains of interest in nootropic and peptide research communities.

Questions still open

• Could different doses, routes of administration, or longer treatment periods produce better results with DSIP?
• Does DSIP's mechanism of action involve sleep regulation at all, or was the original naming premature?
• Are there subgroups of insomnia patients who might respond differently to DSIP?

Common questions

Read the original research

Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

International journal of clinical pharmacology research, 7(2), 105-10

Citation

Monti, J M; Debellis, J; Alterwain, P; Pellejero, T; Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.. International journal of clinical pharmacology research, 7(2), 105-10.